Please login to the form below

Not currently logged in
Email:
Password:

Jounce

This page shows the latest Jounce news and features for those working in and with pharma, biotech and healthcare.

Celgene cuts back Jounce alliance ahead of BMS merger

Celgene cuts back Jounce alliance ahead of BMS merger

Despite the thinning down of the alliance, the news was greeted enthusiastically by Jounce investors, with its shares rising more than 30% on Wednesday. ... Jounce must now deliver positive results from its phase 2 EMERGE clinical trial of vopratelimab

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Licensee. Licensor. Headline. Upfront. Equity. Near-term R&D funding. Celgene. Jounce. $2, 561m. ... Jounce Therapeutics/ Celgene. Portfolio and platform of biomarker driven immuno-oncology therapeutics and CDx.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics